Mr. Adrian Mendes reports

PERIMETER SHOWCASES CLAIRE FOR INTRAOPERATIVE BREAST CANCER MARGIN ASSESSMENT AT ASBRS 2026

Perimeter Medical Imaging AI Inc. has formally unveiled Claire OCT+AI at the upcoming 27th annual meeting of the American Society of Breast Surgeons (ASBrS), April 29 to May 3 in Seattle, Wash.

Claire received United States Food and Drug Administration (FDA) premarket approval (PMA) in March, 2026, becoming the first artificial-intelligence-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment.

Claire combines Perimeter's proprietary AI with its patented wide-field OCT imaging to enable high-resolution, real-time evaluation of excised tumour margins. The system delivers 10 times higher resolution than standard X-ray and ultrasound at two-millimetre imaging depth -- the clinically relevant margin width for breast cancer margin assessment. Claire's innovative AI technology was trained on Perimeter's proprietary and growing OCT image library of over two million breast tissue images. The technology is designed to enhance surgeons' ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for reoperations.

"We're excited to introduce Claire publicly for the first time at the highly regarded ASBrS meeting of more than 1,700 surgeons and health care professionals," said Perimeter chief executive officer Adrian Mendes. "By combining AI with OCT imaging, Claire has the potential to enhance surgical decision making, improve precision and potentially reduce the need for repeat surgeries."

Perimeter is pleased to invite ASBrS attendees to visit booth No. 325 in the Exhibit Hall of the Seattle Convention Center for live demonstrations of Claire, the industry's first FDA-approved real-time AI-powered imaging technology for breast cancer surgery.

About Perimeter Medical Imaging AI Inc.

Based in Toronto, Canada, and Dallas, Tex., Perimeter Medical Imaging is a medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire, recently approved by the U.S. Food and Drug Administration (FDA), is the company's next-generation AI-enabled device. The company's ticker symbol PINK is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Indications for use: The Claire OCT system is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT system is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

The Claire OCT system should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multicentric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labelling for full safety information.

We seek Safe Harbor.